News

Qilu Pharma passed EDQM inspection successfully

ABOUT US

News

Qilu Pharma passed EDQM inspection successfully

Release time：

2015-12-07

Qilu Pharmaceutical Co., Ltd received on-site GMP inspection and CEP registration verification by EDQM as well as the invited regulatory authorities of EU member states from December 2^nd to 4^TH.

A dozen APIs with CEP were approved from this inspection successfully and received the certificate together with EUGMP.

Qilu Synva passed FDA inspection with Zero observation in June 2016

Qilu Pharma launched PEG-rhG-CSF

Related News

Qilu Pharmaceutical ranks No.3 in the list of "Top 100 Enterprises in Chinese Pharmaceutical industry”

2024-09-30

Qilu Launches First Generic Version of Invega Sustenna® (Paliperidone Palmitate Suspension for Injection) in China

2023-10-12

Qilu Pharmaceutical launched the first innovative drug in China

2023-09-01

Qilu Pharmaceutical Group Awarded as Socially Responsible Enterprises (Entrepreneurs) in 2022

2023-04-04

Qilu Pharmaceutical ranks No.5 in the list of "Top 100 Enterprises in Chinese Pharmaceutical Industry”

2022-12-19

Qilu Pharmaceutical ranked 5th among China's top 100 list

2022-07-18

The Most Socially Responsible Enterprises (Entrepreneurs) in 2021

2022-06-15

Qilu Pharmaceutical Awarded as the Best R&D Pipeline Pharmaceutical Company

2021-08-02

Qilu Pharmaceutical Ranked No. 9 among Top 100 Chinese Pharmaceutical Companies

2021-08-01

Qilu Pharmaceutical Acquired an Exclusive Right for the Development and Commercialization of Vicineum™ in Greater China

2021-07-31

Tel: +86-531-83127705, 83127704, 83127706, 83127711

Address: 8888 Lvyou Road, High-tech Zone, Jinan, 250104, China

E mail：export@qilu-pharma.com, FDF@qilu-pharma.com

监督举报

亲爱的合作伙伴：

欢迎举报以下行为！

索贿、暗箱操纵招标、内定中标单位、员工或亲属参与公司业务往来牟取私利、偷工减料、以次充好、故意刁难供应商等行为。

举报电话：0531-83126898/55820713/83126871

举报邮箱：qljc@qilu-pharma.com

收信地址：山东省济南市历城区旅游路8888号

齐鲁制药集团审计监察部

采购平台技术专线

0531-55820865